ReNeuron gets EU stem cell patent:
This article was originally published in Clinica
Executive Summary
UK firm ReNeuron has received a European patent covering key neural stem cell lines and their use as a treatment for stroke, Huntington's disease, Alzheimer's disease, traumatic brain injury and Creutzfeldt-Jakob disease. The patent claims also encompass the use of the cell lines in non-therapeutic applications, such as cell-based screens for testing neurological drug candidates. The Guildford, Surrey firm has already filed for approval to begin US clinical studies of its lead ReN001 stem cell therapy for chronic stroke disability. It has also filed patent applications, which are equivalent to the European on, in the US and in other "significant" territories.